What is Abiochem?
Established in 2015 and headquartered in Shanghai, China, Abiochem operates at the intersection of advanced genetic research and industrial enzyme engineering. The company specializes in developing high-performance biocatalysts that enable more efficient, sustainable, and cost-effective manufacturing processes across various sectors, including pharmaceuticals, food production, and specialty chemicals. By integrating cutting-edge synthetic biology with robust engineering frameworks, Abiochem provides scalable solutions that address the growing demand for green chemistry and precision manufacturing. Its market position is characterized by a commitment to technical excellence and a strategic focus on high-value applications that require sophisticated molecular design and optimization.
How much funding has Abiochem raised?
Abiochem has raised a total of $60.9M across 2 funding rounds:
Series B
$14.9M
Series C
$46M
Series B (2019): $14.9M, investors not publicly disclosed
Series C (2021): $46M led by CMB International Capital and Temasek
Key Investors in Abiochem
CMB International Capital
A subsidiary of China Merchants Bank, this institution provides comprehensive corporate finance services and acts as a major player in the Hong Kong capital market, specializing in IPO sponsorship and structured financing.
Temasek
A global investment company headquartered in Singapore that operates as a generational investor, focusing on long-term value creation and sustainable growth across diverse sectors.
Undisclosed Investors
What's next for Abiochem?
With the successful closure of its latest funding round, Abiochem is poised to enter a new phase of enterprise-level expansion. The strategic roadmap likely involves the scaling of its proprietary enzyme production facilities and the deepening of its R&D pipeline to address emerging challenges in sustainable manufacturing. Furthermore, the company is expected to leverage its strengthened balance sheet to pursue international partnerships and talent acquisition, ensuring it remains at the forefront of the global biotechnology revolution. As the industry shifts toward more sustainable and efficient production methods, Abiochem's focus on high-tech genetic engineering positions it as a key enabler of the next generation of industrial processes. The firm's ability to attract top-tier institutional backing suggests a long-term commitment to maintaining its leadership in the synthetic biology space, with a clear focus on delivering measurable value to its global client base.
See full Abiochem company page
